1. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
- Author
-
Veras ASC, Batista VRG, Correia RR, de Almeida Tavares ME, Rubira RJG, Tavares ER, Giometti IC, Maranhão RC, and Teixeira GR
- Subjects
- Male, Humans, Animals, Emulsions, Cell Line, Tumor, Apoptosis drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Mice, Lipids blood, Disease Progression, Exercise, Nanoparticles chemistry, Cell Proliferation drug effects, Physical Conditioning, Animal, Docetaxel pharmacology, Docetaxel therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Prostatic Neoplasms metabolism
- Abstract
The variability in response to conventional prostate cancer (PC) therapies, coupled with the emergent issue of drug resistance, underscores the critical need for innovative treatment strategies. Aerobic physical exercise reduced incidence of several cancers, but the mechanism underlying these effects associated the nanoemulsion not fully understood. The application of a lipid nanoemulsion (LDE) delivery system for docetaxel (DTX), showing marked enhancement in therapeutic efficacy when combined with aerobic physical exercise. This novel intervention potentiates the antitumor activity of LDE-delivered DTX by augmenting nanoparticle internalization and inducing cell cycle arrest. Our findings reveal that this synergistic treatment not only significantly reduces prostate weight and mitigates adenocarcinoma proliferation but also attenuates anti-apoptotic BCL-2 protein expression. Concurrently, it elevates pro-apoptotic proteins and diminishes inflammatory markers. Metabolic profiling of the combined therapy group disclosed additional benefits, such as reduced lipid and plasma glucose levels. Collectively, our data illuminate the profound impact of integrating LDE-mediated DTX delivery with structured physical exercise, which together spearhead a dual-front assault on PC. This multimodal approach heralds a new paradigm in PC management, accentuating the promise of combined pharmacological and non-pharmacological interventions to elevate tumor suppressor protein activity and refine patient outcomes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF